- Home
- ACRS vs SUNS Comparison
ACRS vs SUNS Comparison
Compare ACRS & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SUNS
- Stock Information
- Founded
- ACRS 2012
- SUNS 2023
- Country
- ACRS United States
- SUNS United States
- Employees
- ACRS N/A
- SUNS N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SUNS Real Estate Investment Trusts
- Sector
- ACRS Health Care
- SUNS Real Estate
- Exchange
- ACRS Nasdaq
- SUNS Nasdaq
- Market Cap
- ACRS 127.6M
- SUNS 148.2M
- IPO Year
- ACRS 2015
- SUNS N/A
- Fundamental
- Price
- ACRS $1.14
- SUNS $9.06
- Analyst Decision
- ACRS Strong Buy
- SUNS Strong Buy
- Analyst Count
- ACRS 7
- SUNS 3
- Target Price
- ACRS $11.67
- SUNS $13.42
- AVG Volume (30 Days)
- ACRS 968.2K
- SUNS 165.4K
- Earning Date
- ACRS 05-06-2025
- SUNS 05-07-2025
- Dividend Yield
- ACRS N/A
- SUNS 10.23%
- EPS Growth
- ACRS N/A
- SUNS N/A
- EPS
- ACRS N/A
- SUNS 1.00
- Revenue
- ACRS $18,720,000.00
- SUNS $10,588,270.00
- Revenue This Year
- ACRS N/A
- SUNS $141.80
- Revenue Next Year
- ACRS $425.96
- SUNS $53.98
- P/E Ratio
- ACRS N/A
- SUNS $9.06
- Revenue Growth
- ACRS N/A
- SUNS 1342.10
- 52 Week Low
- ACRS $0.95
- SUNS $7.80
- 52 Week High
- ACRS $5.17
- SUNS $15.74
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- SUNS N/A
- Support Level
- ACRS $1.05
- SUNS N/A
- Resistance Level
- ACRS $1.23
- SUNS N/A
- Average True Range (ATR)
- ACRS 0.11
- SUNS 0.00
- MACD
- ACRS -0.01
- SUNS 0.00
- Stochastic Oscillator
- ACRS 16.82
- SUNS 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.